Next Article in Journal
Considerations for Individual-Level Versus Whole-School Physical Activity Interventions: Stakeholder Perspectives
Previous Article in Journal
“Suck It Up, Buttercup”: Understanding and Overcoming Gender Disparities in Policing
Previous Article in Special Issue
Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement
 
 
Review

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, 40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Atsushi Nonami
Int. J. Environ. Res. Public Health 2021, 18(14), 7629; https://doi.org/10.3390/ijerph18147629
Received: 25 May 2021 / Revised: 5 July 2021 / Accepted: 6 July 2021 / Published: 18 July 2021
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS. View Full-Text
Keywords: myelodysplastic syndromes; guidelines; patient reported outcome; prognosis myelodysplastic syndromes; guidelines; patient reported outcome; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Kasprzak, A.; Kaivers, J.; Nachtkamp, K.; Haas, R.; Kobbe, G.; Gattermann, N.; Germing, U. Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? Int. J. Environ. Res. Public Health 2021, 18, 7629. https://doi.org/10.3390/ijerph18147629

AMA Style

Kasprzak A, Kaivers J, Nachtkamp K, Haas R, Kobbe G, Gattermann N, Germing U. Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? International Journal of Environmental Research and Public Health. 2021; 18(14):7629. https://doi.org/10.3390/ijerph18147629

Chicago/Turabian Style

Kasprzak, Annika, Jennifer Kaivers, Kathrin Nachtkamp, Rainer Haas, Guido Kobbe, Norbert Gattermann, and Ulrich Germing. 2021. "Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?" International Journal of Environmental Research and Public Health 18, no. 14: 7629. https://doi.org/10.3390/ijerph18147629

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop